These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37550074)

  • 1. Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception.
    Demortiere S; Maarouf A; Rico A; Boutiere C; Hilezian F; Durozard P; Pelletier J; Audoin B
    Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37550074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.
    Razaz N; Piehl F; Frisell T; Langer-Gould AM; McKay KA; Fink K
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33087582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.
    Graille-Avy L; Boutiere C; Rigollet C; Perriguey M; Rico A; Demortiere S; Durozard P; Hilezian F; Vely F; Bertault-Peres P; Pelletier J; Maarouf A; Audoin B
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200231. PubMed ID: 38626360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
    Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
    Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
    Boremalm M; Juto A; Axelsson M; Novakova L; Frisell T; Svenningsson A; Lycke J; Piehl F; Salzer J
    Eur J Neurol; 2019 Aug; 26(8):1060-1067. PubMed ID: 30762259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany.
    Kümpfel T; Thiel S; Meinl I; Ciplea AI; Bayas A; Hoffmann F; Hofstadt-van Oy U; Hoshi M; Kluge J; Ringelstein M; Aktas O; Stoppe M; Walter A; Weber MS; Ayzenberg I; Hellwig K
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33334856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    Muñoz-Vendrell A; Arroyo-Pereiro P; León I; Bau L; Matas E; Martínez-Yélamos A; Martínez-Yélamos S; Romero-Pinel L
    J Neurol; 2023 May; 270(5):2559-2566. PubMed ID: 36913038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Demortiere S; Rico A; Maarouf A; Boutiere C; Pelletier J; Audoin B
    Mult Scler; 2021 Apr; 27(5):712-718. PubMed ID: 32202216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.
    Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T
    Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.
    Mustonen T; Rauma I; Hartikainen P; Krüger J; Niiranen M; Selander T; Simula S; Remes AM; Kuusisto H
    Mult Scler Relat Disord; 2020 Feb; 38():101498. PubMed ID: 31864192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
    Hemmer B; Wiendl H; Roth K; Wessels H; Höfler J; Hornuss C; Liedert B; Selmaj K
    JAMA Neurol; 2023 Mar; 80(3):298-307. PubMed ID: 36689214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab, MS, and pregnancy.
    Smith JB; Hellwig K; Fink K; Lyell DJ; Piehl F; Langer-Gould A
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32358226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years.
    Auer M; Zinganell A; Hegen H; Bsteh G; Di Pauli F; Berek K; Fava E; Wurth S; Berger T; Deisenhammer F
    Sci Rep; 2021 Dec; 11(1):23317. PubMed ID: 34857795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review.
    Brown JD; Muston BT; Massey J
    Mult Scler Relat Disord; 2024 Jun; 86():105605. PubMed ID: 38640586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30).
    Valero-López G; Millán-Pascual J; Iniesta-Martínez F; Delgado-Marín JL; Jimenez-Veiga J; Tejero-Martín AB; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2022 Oct; 66():104038. PubMed ID: 35870370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
    Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
    J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.